Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound particles for treating retinal vasculitis and preparation method thereof

A vasculitis and retinal technology, applied in the field of compound granules for the treatment of retinal vasculitis and their preparation, can solve the problems of retinal edema, cystoid macular edema, proliferative changes, etc. promising effect

Inactive Publication Date: 2016-06-22
刘文霞
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The patient has no obvious retinal hemorrhage, vascular sheath, new blood vessel and other changes, but the patient may have mild retinal edema, cystoid macular edema, and proliferative changes may also appear in patients with long-term chronic inflammation. retinal microvascular leak

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Embodiment 1: A kind of compound granule for the treatment of retinal vasculitis, comprises the following main components by weight components: 45 parts of cortisol, 38 parts of prednisone, 36 parts of chlorambucil, anti-lymphocyte antibody 24 parts, 20 parts of rifampin, 19 parts of peat moss fermented powder, 12 parts of moxicelib, 10 parts of escin, 8 parts of lecithin, 5 parts of anisodine, 4 parts of zinc gluconate, 2 parts of cod liver oil parts; and auxiliary material components: 1 part of flavoring agent, 0.1 part of surfactant, and 0.01 part of preservative.

[0018] Wherein, the Sphagnum tenifolia fermentation powder is fermented by adding a mixture of Aspergillus oryzae, Aspergillus niger, Mucor and yeast in an environment soaked in sodium chloride solution, and the preparation method is as follows: take shade-dried Sphagnum tenifolia dry product, crushed through a 100-mesh sieve, then adding 45% sodium chloride solution with a mass concentration of 10 times ...

Embodiment 2

[0024] Embodiment 2: A kind of compound granule for the treatment of retinal vasculitis, comprises the following main components by weight components: 52.5 parts of cortisol, 41.5 parts of prednisone, 39.5 parts of chlorambucil, anti-lymphocyte antibody 30 parts, 25 parts of rifampicin, 22.5 parts of peat moss fermented powder, 15.5 parts of moxicelib, 12.5 parts of aescin, 10.5 parts of lecithin, 7.5 parts of anisodine, 6 parts of zinc gluconate, 3 parts of cod liver oil parts; and auxiliary material components: 2 parts of flavoring agent, 0.15 part of surfactant, 0.02 part of preservative.

[0025] Wherein, the Sphagnum tenifolia fermentation powder is fermented by adding a mixture of Aspergillus oryzae, Aspergillus niger, Mucor and yeast in an environment soaked in sodium chloride solution, and the preparation method is as follows: take shade-dried Sphagnum tenifolia dry product, crushed through a 100-mesh sieve, then adding 45% sodium chloride solution with a mass concentr...

Embodiment 3

[0031] Embodiment 3: A kind of compound granule for treating retinal vasculitis, comprises the following main components by weight components: 60 parts of cortisol, 45 parts of prednisone, 43 parts of chlorambucil, anti-lymphocyte antibody 36 parts, 30 parts of rifampicin, 28 parts of sphagnum moss, 19 parts of moses, 15 parts of escin, 13 parts of lecithin, 10 parts of anisodine, 8 parts of zinc gluconate, 4 parts of cod liver oil and accessories: 3 parts of flavoring agent, 0.2 part of surfactant, and 0.03 part of preservative.

[0032] Wherein, the Sphagnum tenifolia fermentation powder is fermented by adding a mixture of Aspergillus oryzae, Aspergillus niger, Mucor and yeast in an environment soaked in sodium chloride solution, and the preparation method is as follows: take shade-dried Sphagnum tenifolia dry product, crushed through a 100-mesh sieve, then adding 45% sodium chloride solution with a mass concentration of 20 times the weight of the powder to the Sphagnum teni...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses compound particles for treating retinal vasculitis and a preparation method thereof. The compound particles for treating the retinal vasculitis are prepared from cortisol, prednisone, chlorambucil, an antilymphocyte antibody, rifampicin, thin-leaf sphagnum fermented powder, moxisylyte, aesculin, lecithin, anisodine, zinc gluconate, cod liver oil, dl-alpha tocopherol, inosine, wheat germ oil and magnet powder. The compound particles combine with a variety of pharmaceutical ingredients, achieve anti-inflammatory, anti-bacterial, liver-protecting, eyesight-improving and body immunity regulating effects through combined action and have the remarkable effect of treating the retinal vasculitis. In addition, the compound particles have small side effects, do not produce the adverse effect on the eyesight and the bodies of patients after long-term taking and are wide in application prospect.

Description

technical field [0001] The invention relates to the technical field of ophthalmic medicine, in particular to a compound granule for treating retinal vasculitis and a preparation method thereof. Background technique [0002] Retinal vasculitis is a large group of inflammatory diseases involving retinal blood vessels. Typical manifestations are gray-white vascular sheath, exudation, hemorrhage, retinal edema and other changes in the fundus, and only invasion of arteries or veins is rare. Most are affected by both. Ocular or systemic diseases often accompanied by retinal vasculitis include: intermediate uveitis, viral retinitis, systemic lupus erythematosus, Takayasu arteritis, sarcoidosis, etc. [0003] Retinal vasculitis can be divided into three types: arteritis, phlebitis, and capillary vasculitis. The clinical manifestations are different. Retinal phlebitis and retinal perivenous inflammation are common types in retinal vasculitis. Clinically, it mainly manifests as the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61K9/16A61P27/02A61K36/899A61K35/60A61K33/26A61K31/7076A61K31/7048A61K31/685A61K31/573A61K31/496A61K31/439A61K31/355A61K31/315A61K31/222A61K31/196
CPCA61K39/39541A61K9/1652A61K31/196A61K31/222A61K31/315A61K31/355A61K31/439A61K31/496A61K31/573A61K31/685A61K31/7048A61K31/7076A61K33/26A61K35/60A61K36/10A61K36/899A61K2300/00
Inventor 刘文霞
Owner 刘文霞
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com